

Elevation Oncology to Participate at Upcoming Virtual Investor Conferences

NEW YORK, March 1, 2022 /[PRNewswire](#)/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced that Shawn M. Leland, PharmD, RPh, Elevation Oncology's Founder and Chief Executive Officer, will participate in the following investor conferences in March:

Cowen 42nd Annual Health Care Conference

Date: Tuesday, March 8

Panel Title: Tumor Agnostic Development

Panel Time: 12:50 p.m. ET

Oppenheimer 32nd Annual Healthcare Conference

Date: Wednesday, March 16

Presentation Time: 12:40 p.m. ET

A live webcast and replay of these events will be available on the [Events](#) page of the Company's Investor Relations website at <https://investors.elevationoncology.com/events>.

About Elevation Oncology, Inc.

Elevation Oncology is founded on the belief that every patient living with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. We aim to make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of tumor growth. Together with our peers, we work towards a future in which each tumor's unique genomic test result can be matched with a purpose-built precision medicine to enable an individualized treatment plan for each patient. Our lead candidate, seribantumab, is intended to inhibit tumor growth driven by [NRG1 fusions](#) and is currently being evaluated in the [Phase 2 CRESTONE study](#) for patients with solid tumors of any origin that have an NRG1 gene fusion. Details on CRESTONE are available at www.NRG1fusion.com. For more information visit www.ElevationOncology.com.

Elevation Oncology Investor and Media Contact

Candice Masse, 978-879-7273

Senior Director, Corporate Communications & Investor Relations

cmasse@elevationoncology.com

SOURCE Elevation Oncology

<https://investors.elevationoncology.com/2022-03-01-Elevation-Oncology-to-Participate-at-Upcoming-Virtual-Investor-Conferences>